Bart DeplanckeEnseignement et PhD Doctorant·es actuel·les Wenyu Liu, Théo Nass, Augoustina Maria Economou, Horia Hashimi, Timothée Ferrari, Loïc David, Laurine Cécile Florentine Van Gijn, Angelika Gebhart, Camille Lucie Germaine Lambert, Marie Denise Rumpler, Antoni Jakub Gralak, Elisa Bugani, Geoffray Marie-Devillard A dirigé les thèses EPFL de Jovan Simicevic, Carine Delattre-Gubelmann, Andreas Massouras, Irina Krier, Alina Isakova, Sebastian Martin Waszak, Rachana Narendra Pradhan, Adamandia Kapopoulou, Roel Bevers,
Pierre GönczyExpertise
Cell divisionPolarityAsymmetric divisionMicrotubulesCentrioleSAS-6C-elegans
Enseignement et PhD Doctorant·es actuel·les Cédric Pourroy, Friso Douma, Dessislava Iliyanova Ilieva, Alana Dastous, Ella Linxia Müller, Sanne Wijma A dirigé les thèses EPFL de Gregor Kohlmaier, Kalyani Thyagarajan, Alexandra Bezler, Debora Keller, Simon Blanchoud, Lukas von Tobel, Christian Gentili, Zoltán Péter Spiró, Alessandro De Simone, Veronika Nemcíková Villímová, Melina Jasmin Scholze, Radek Jankele, Nils Kalbfus
Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Cathrin BriskenExpertise
Breast cancer; endocrine control mechanisms, precision medicine, patient derived models; estrogen, progesterone,and androgen receptor signaling, Mammary Gland Development, Endocrine Disruptors
Mission
Cathrin Brisken obtained MD and PhD in Biophysics from the University of Göttingen, Germany, did postdoctoral work at the Whitehead Institute, MIT, Cambridge, USA, and held appointments at the Whitehead Institute, the Cancer Center of the Massachusetts General Hospital, Harvard Medical School and the
Jörg HülskenProf. Joerg Huelsken received his PhD in 1998 at the Humboldt University and did postdoctoral research in the laboratory of Walter Birchmeier at the Max-Delbrueck Center for Molecular Medicine, Berlin. He joined ISREC as an associate scientist and an NCCR project leader in January 2003 and, in 2005, was nominated Tenure Track Assistant Professor at the EPFL School of Life Sciences.
